ArticleJournal of neuroinflammation2025
Chemokine-complement cascade in glial-vascular units protects neurons from non-biogenic nanoparticles.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bridging environmental pollution and immune dysregulation: How microplastics disrupt gut homeostasis to promote allergic diseases.Virulence · 2026Review
- Liver-derived complement component 3 promotes the susceptibility to stress-induced depression by impairing blood-brain barrier integrity.Molecular psychiatry · 2026Article
- Axonopathy: mechanisms and potential therapeutic targets for neurodegenerative diseases.Translational neurodegeneration · 2026Review
- Ozone-induced cognitive deficits are mediated by the liver-brain axis: peripheral complement C3 triggers microglial synaptic phagocytosis.Journal of neuroinflammation · 2026Article
- Cognitive impairment after cerebral ischemia-reperfusion injury: a neuroecosystem perspective.Frontiers in neurology · 2026Review
- Review
- Multifunctional Nanoparticles in Traumatic Brain Injury: From Targeted Imaging and Diagnosis to Innovative Therapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Non-biogenic nanoparticles (NPs), including silica and polystyrene, are major components of environmental particulate pollution and can accumulate in the brain, especially during development when the blood-brain barrier is immature, leading to neurotoxicity. However, protective responses within the brain to these NPs remain poorly understood. Here, using a developing mouse model, we show that microglia phagocytose non-biogenic NPs through a complement-dependent mechanism involving C3 tagging. This process is regulated by a chemokine cascade in which vascular endothelial cells release CCL17, activating CCR4 on perivascular astrocytes to promote astrocytic C3 production. Inhibition of CCR4 signaling suppresses C3 production, impairs microglial phagocytosis, increases neuronal loss, and exacerbates anxiety-like behaviors. Our data establish a protective role for the vascular-glial chemokine-complement axis in limiting neurotoxicity during brain development. These findings reveal a coordinated immune response to non-biogenic environmental NPs and uncover a vascular-glial mechanism that mitigates NP-induced brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.